1. Schultz,N.H., Sørvoll,I.H., Michelsen,A.E., Munthe,L.A., Lund-Johansen,F., Ahlen,M.T., Wiedmann,M., Aamodt,A.-H., Skattør,T.H., Tjønnfjord,G.E., et al. (2021) Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. N. Engl. J. Med., 384, 2124–2130.
2. Greinacher,A., Thiele,T., Warkentin,T.E., Weisser,K., Kyrle,P.A. and Eichinger,S. (2021) Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. N. Engl. J. Med., 384, 2092–2101.
3. Pharmacovigilance Risk Assessment Committee (PRAC) (2021) Signal assessment report on embolic and thrombotic events (SMQ) with COVID-19 Vaccine (ChAdOx1-S [recombinant]) – COVID-19 Vaccine AstraZeneca (Other viral vaccines). Eur. Med. Agency.
4. Sadoff,J., Davis,K. and Douoguih,M. (2021) Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination — Response from the Manufacturer. N. Engl. J. Med., 384, 1965–1966.
5. Michalik,S., Siegerist,F., Franzke,K., Schindler,M., Seifert,U. and Beer,M. (2021) Comparative analysis of ChAdOx1 nCoV-19 and Ad26.COV2.S SARS-CoV-2 vector vaccines. researchsquare, 10.21203/rs.3.rs-736157/v1.
6. Baker,A.T., Boyd,R.J., Sarkar,D., Vant,J., Crespo,A.T., Truong,C.D., Bates,E., Wilson,E., Chan,C.K., Lipka-Lloyd,M., et al. (2021) The Structure of ChAdOx1/AZD-1222 Reveals Interactions with CAR and PF4 with Implications for Vaccine-induced Immune Thrombotic Thrombocytopenia. bioRxiv, 10.1101/2021.05.19.444882.
7. Kowarz,E., Krutzke,L., Reis,J., Bracharz,S., Kochanek,S. and Marschalek,R. (2021) Vaccine-Induced Covid-19 Mimicry” Syndrome:Splice reactions within the SARS-CoV-2 Spike open reading frame result in Spike protein variants that may cause thromboembolic events in patients immunized with vector-based vaccines. researchsquare, 10.21203/rs.3.rs-558954/v1.
8. Dicks,M.D.J., Spencer,A.J., Edwards,N.J., Wadell,G., Bojang,K., Gilbert,S.C., Hill,A.V.S. and Cottingham,M.G. (2012) A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity. PLoS One, 7, e40385.
9. van Doremalen,N., Lambe,T., Spencer,A., Belij-Rammerstorfer,S., Purushotham,J.N., Port,J.R., Avanzato,V.A., Bushmaker,T., Flaxman,A., Ulaszewska,M., et al. (2020) ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature, 586, 578–582.
10. Badbaran,A., Mailer,R., Dahlke,C., Woens,J., Fathi,A., Mellinghoff,S.C., Renné,T., Addo,M.M., Riecken,K. and Fehse,B. (2021) Digital PCR to quantify ChAdOx1 nCoV-19 copies in blood and tissues. bioRxiv, 10.1101/2021.05.28.446155.
11. Stephen,S.L., Montini,E., Sivanandam,V.G., Al-Dhalimy,M., Kestler,H.A., Finegold,M., Grompe,M. and Kochanek,S. (2010) Chromosomal integration of adenoviral vector DNA in vivo. J. Virol., 84, 9987–94.
12. Fischer,R.J., van Doremalen,N., Adney,D.R., Yinda,C.K., Port,J.R., Holbrook,M.G., Schulz,J.E., Williamson,B.N., Thomas,T., Barbian,K., et al. (2021) ChAdOx1 nCoV-19 (AZD1222) protects hamsters against SARS-CoV-2 B.1.351 and B.1.1.7 disease. bioRxiv Prepr. Serv. Biol., 10.1101/2021.03.11.435000.
13. Radukic,M.T., Brandt,D., Haak,M., Müller,K.M. and Kalinowski,J. (2020) Nanopore sequencing of native adeno-associated virus (AAV) single-stranded DNA using a transposase-based rapid protocol. NAR genomics Bioinforma., 2, lqaa074.
14. Almuqrin,A., Davidson,A.D., Williamson,M.K., Lewis,P.A., Heesom,K.J., Morris,S., Gilbert,S.C. and Matthews,D.A. (2021) SARS-CoV-2 vaccine ChAdOx1 nCoV-19 infection of human cell lines reveals low levels of viral backbone gene transcription alongside very high levels of SARS-CoV-2 S glycoprotein gene transcription. Genome Med., 13, 43.
15. Schagen,F.H.E., Rademaker,H.J., Rabelink,M.J.W.E., van Ormondt,H., Fallaux,F.J., van der Eb,A.J. and Hoeben,R.C. (2000) Ammonium sulphate precipitation of recombinant adenovirus from culture medium: an easy method to increase the total virus yield. Gene Ther., 7, 1570–1574.
16. U.S. Food and Drug Administration (2010) Guidance for Industry; Cell Characterization and Qualification of Cell Substrates and Other Biological Materials Used in the Production of Viral Vaccines for Infectious Disease Indications.
17. Kolmogorov,M., Yuan,J., Lin,Y. and Pevzner,P.A. (2019) Assembly of long, error-prone reads using repeat graphs. Nat. Biotechnol., 37, 540–546.
18. Li,H. (2018) Minimap2: pairwise alignment for nucleotide sequences. Bioinformatics, 34, 3094–3100.
19. Altschul,S.F., Gish,W., Miller,W., Myers,E.W. and Lipman,D.J. (1990) Basic local alignment search tool. J. Mol. Biol., 215, 403–10.
20. European Medicines Agency (2021) COVID-19 Vaccine AstraZeneca - Product Information as approved by the CHMP on 29 January 2021, pending endorsement by the European Commission.
21. Hanke,T., Schneider,J., Gilbert,S.C., Hill,A. V and McMichael,A. (1998) DNA multi-CTL epitope vaccines for HIV and Plasmodium falciparum: immunogenicity in mice. Vaccine, 16, 426–35.
22. European Directorate for the Quality of Medicines & Healthcare EDQM (2020) EUROPEAN PHARMACOPOEIA: Free access to supportive pharmacopoeial texts in the field of vaccines for human use during the coronavirus disease (COVID-19) pandemic.
23. Zentrale Kommission für die Biologische Sicherheit (2020) Empfehlung der ZKBS zur Risikobewertung des rekombinanten Adenovirus ChAdOx1 nCoV-19 gemäß § 5 Absatz 1 GenTSV, Az. 45242.0181.
24. AstraZeneca (2020) AZD1222 Safety Data Sheet, Australia, Ver 1.1, Rev. 02.12.2020, SDS No. 25943.